PLEVITREXED

• CAT Number: M090629
• CAS Number: 153538-08-0
• Molecular Formula: C26H25FN8O4
• Molecular Weight: 532.54
• Purity: ≥95%
• Target: Thymidylate Synthase
• Storage: -20°C
• IUPAC Name: 2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
• InChI: InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)
• InChIKey: IEJSCSAMMLUINT-UHFFFAOYSA-N
• SMILES: CC1=C(C=C2C(=C1)NC(=NC2=O)C)CN(CC#C)C3=CC(=C(C=C3)C(=O)NC(CCC4=NNN=N4)C(=O)O)F

Pemetrexed (brand name Alimta) (Cat No.: M090629) is a chemotherapy drug used to treat certain cancers, including non-small cell lung cancer (NSCLC) and mesothelioma. It works by inhibiting folate-dependent enzymes involved in DNA synthesis, particularly thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This action prevents the growth and division of cancer cells. Pemetrexed is typically used in combination with other chemotherapy agents and may cause side effects such as nausea, fatigue, and myelosuppression, requiring close monitoring during treatment.